Neuronetics Inc
STIM1.400USD
-0.015-1.06%
收盤 12/19, 16:00（美東）報價延遲15分鐘
95.82M總市值
虧損本益比TTM
關於 Neuronetics Inc 公司
Neuronetics, Inc. a vertically integrated, commercial stage, medical technology and healthcare company. The Company’s NeuroStar Advanced Therapy (NeuroStar Therapy) is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions. In addition to selling the NeuroStar Advanced Therapy System (NeuroStar System) and associated treatment sessions to customers, it operates Greenbrook treatment centers across the United States, offering NeuroStar Therapy for the treatment of major depressive disorder (MDD) and other mental health disorders. Spravato is offered to treat adults with treatment-resistant depression and depressive symptoms in adults with MDD with suicidal thoughts or actions. MDD is a recurrent disease and follows a fluctuating course over an individual’s lifetime. The Company provides more than 7.1 million treatments to over 1,95,000 patients.
Neuronetics Inc簡介
公司代碼STIM
公司名稱Neuronetics Inc
上市日期Jun 28, 2018
CEOMr. Keith J. Sullivan
員工數量716
證券類型Ordinary Share
年結日Jun 28
公司地址3222 Phoenixville Pike
城市MALVERN
上市交易所NASDAQ OMX - NASDAQ BASIC
國家United States of America
郵編19355
電話18776007555
網址https://neurostar.com/neuronetics/
公司代碼STIM
上市日期Jun 28, 2018
CEOMr. Keith J. Sullivan
Neuronetics Inc公司高管
名稱
名稱/職務
職務
持股
持股變動
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+0.32%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+1.82%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
400.00K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+2.30%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+4.12%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+27.05%
Mr. W. Andrew Macan
Mr. W. Andrew Macan
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary
--
--
Dr. Avinash N. Amin, M.D.
Dr. Avinash N. Amin, M.D.
Director
Director
--
--
Mr. Mark Klausner
Mr. Mark Klausner
Managing Partner
Managing Partner
--
--
名稱
名稱/職務
職務
持股
持股變動
Mr. Sasha Cucuz
Mr. Sasha Cucuz
Director
Director
2.03M
+0.32%
Mr. Robert A. (Rob) Cascella
Mr. Robert A. (Rob) Cascella
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
588.77K
+1.82%
Mr. Steven Pfanstiel
Mr. Steven Pfanstiel
Chief Financial Officer, Executive Vice President, Treasurer
Chief Financial Officer, Executive Vice President, Treasurer
400.00K
--
Mr. Glenn P. Muir
Mr. Glenn P. Muir
Independent Director
Independent Director
335.45K
+2.30%
Ms. Sheryl L. Conley
Ms. Sheryl L. Conley
Independent Director
Independent Director
185.35K
+4.12%
Ms. Megan Rosengarten
Ms. Megan Rosengarten
Independent Director
Independent Director
140.89K
+27.05%
收入明細
單位: USD更新時間: 10月6日 週一
單位: USD更新時間: 10月6日 週一
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
業務USD
名稱
營收
佔比
Clinic revenue
23.02M
60.42%
Treatment sessions
11.05M
29.00%
NeuroStar Advanced Therapy System
3.65M
9.57%
Other
385.00K
1.01%
地區USD
名稱
營收
佔比
United States
37.66M
98.81%
International
452.00K
1.19%
業務
地區
業務USD
名稱
營收
佔比
Clinic revenue
23.02M
60.42%
Treatment sessions
11.05M
29.00%
NeuroStar Advanced Therapy System
3.65M
9.57%
Other
385.00K
1.01%
股東統計
更新時間: 11月26日 週三
更新時間: 11月26日 週三
持股股東
股東類型
持股股東
持股股東
佔比
Madryn Asset Management, LP
30.28%
Chernett (Jorey)
6.43%
The Vanguard Group, Inc.
4.14%
UBS Financial Services, Inc.
3.16%
BlackRock Institutional Trust Company, N.A.
3.10%
其他
52.90%
持股股東
持股股東
佔比
Madryn Asset Management, LP
30.28%
Chernett (Jorey)
6.43%
The Vanguard Group, Inc.
4.14%
UBS Financial Services, Inc.
3.16%
BlackRock Institutional Trust Company, N.A.
3.10%
其他
52.90%
股東類型
持股股東
佔比
Private Equity
30.28%
Individual Investor
15.58%
Investment Advisor
13.62%
Hedge Fund
9.59%
Investment Advisor/Hedge Fund
6.10%
Research Firm
1.71%
Bank and Trust
0.11%
Pension Fund
0.05%
Venture Capital
0.04%
其他
22.92%
機構持股
更新時間: 10月1日 週三
更新時間: 10月1日 週三
報告期間
機構數
持股數
持股佔比
持股變動
2025Q3
198
39.45M
57.60%
-13.65M
2025Q2
187
47.56M
71.93%
-4.03M
2025Q1
191
47.19M
71.70%
-4.84M
2024Q4
155
36.70M
70.38%
+11.74M
2024Q3
153
14.58M
47.42%
-9.85M
2024Q2
159
20.22M
66.61%
-5.87M
2024Q1
183
20.38M
68.24%
-3.49M
2023Q4
191
18.37M
63.28%
-7.87M
2023Q3
201
19.69M
68.24%
-8.69M
2023Q2
222
21.10M
73.37%
-11.20M
查看更多
股東持股明細
名稱
持股數
佔比
持股變動
變動比例
公告日期
Madryn Asset Management, LP
20.74M
31.36%
-3.50M
-14.44%
Aug 08, 2025
The Vanguard Group, Inc.
2.74M
4.15%
+436.54K
+18.93%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
2.05M
3.1%
+1.67M
+440.36%
Jun 30, 2025
Cucuz (Sasha)
2.02M
3.06%
+30.00K
+1.50%
May 22, 2025
Balyasny Asset Management LP
1.51M
2.28%
+92.05K
+6.50%
Jun 30, 2025
Sullivan (Keith J)
1.61M
2.43%
--
--
Mar 24, 2025
Wexford Capital LP
643.07K
0.97%
+171.34K
+36.32%
Jun 30, 2025
Masters Capital Management, L.L.C.
1.00M
1.51%
--
--
Jun 30, 2025
查看更多
持股ETF
更新時間: 12月6日 週六
更新時間: 12月6日 週六
機構名稱
佔比
AdvisorShares Psychedelics ETF
3.31%
Invesco NASDAQ Future Gen 200 ETF
0.43%
iShares Neuroscience and Healthcare ETF
0.1%
Vanguard US Momentum Factor ETF
0.04%
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.01%
Avantis US Small Cap Equity ETF
0%
ProShares Hedge Replication ETF
0%
Proshares Ultra Russell 2000
0%
查看更多
AdvisorShares Psychedelics ETF
佔比3.31%
Invesco NASDAQ Future Gen 200 ETF
佔比0.43%
iShares Neuroscience and Healthcare ETF
佔比0.1%
Vanguard US Momentum Factor ETF
佔比0.04%
iShares Micro-Cap ETF
佔比0.02%
iShares Russell 2000 Growth ETF
佔比0.01%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
佔比0.01%
Avantis US Small Cap Equity ETF
佔比0%
ProShares Hedge Replication ETF
佔比0%
Proshares Ultra Russell 2000
佔比0%
分紅派息
近5年累計派現
0.00
美元
公告日期
分紅計劃
股權登記日
現金發放日
除權除息日
暫無數據
拆合股
公告日期
類型
比率
暫無數據
公告日期
類型
比率
暫無數據
常見問題
Neuronetics Inc的前五大股東是誰？
Neuronetics Inc的前五大股東如下：
Madryn Asset Management, LP持有股份：20.74M佔總股份比例：31.36%。
The Vanguard Group, Inc.持有股份：2.74M佔總股份比例：4.15%。
BlackRock Institutional Trust Company, N.A.持有股份：2.05M佔總股份比例：3.10%。
Cucuz (Sasha)持有股份：2.02M佔總股份比例：3.06%。
Balyasny Asset Management LP持有股份：1.51M佔總股份比例：2.28%。
Madryn Asset Management, LP持有股份：20.74M佔總股份比例：31.36%。
The Vanguard Group, Inc.持有股份：2.74M佔總股份比例：4.15%。
BlackRock Institutional Trust Company, N.A.持有股份：2.05M佔總股份比例：3.10%。
Cucuz (Sasha)持有股份：2.02M佔總股份比例：3.06%。
Balyasny Asset Management LP持有股份：1.51M佔總股份比例：2.28%。
Neuronetics Inc的前三大股東類型是什麼？
Neuronetics Inc 的前三大股東類型分別是：
Madryn Asset Management, LP
Chernett (Jorey)
The Vanguard Group, Inc.
Madryn Asset Management, LP
Chernett (Jorey)
The Vanguard Group, Inc.
有多少機構持有Neuronetics Inc(STIM)的股份？
截至2025Q3，共有198家機構持有Neuronetics Inc的股份，合計持有的股份價值約為39.45M，占公司總股份的57.60% 。與2025Q2相比，機構持股有所增加，增幅為-14.33%。
哪個業務部門對Neuronetics Inc的收入貢獻最大？
在FY2025Q2，Clinic revenue業務部門對Neuronetics Inc的收入貢獻最大，創收23.02M，占總收入的60.42% 。
